The use of long acting antipsychotics in outpatient care

Close metadata

OBJECTIVE

To determine the frequency of administration, efficacy and safety of long acting antipsychotics in day-to-day psychiatric practice in outpatient clinics.

MATERIAL AND METHODS

The study included 90 patients with schizophrenia treated with haloperidol decanoate (n=18), rispolept consta (n=19), clopixol depot (n=25), paliperidone palmitate (n=25). Symptoms of schizophrenia were assessed with PANSS during 12 months.

RESULTS AND CONCLUSION

The use of long acting antipsychotics has proven to be effective and safe to control all symptom clusters in patients regardless of the disease duration.

Keywords:

schizophrenia

long acting antipsychotics

positive symptoms

negative symptoms

outpatient care

Authors:

Kurmyshev M.V.

Alekseev Psychiatrc Clinical Hospital No. 1

Zaytseva M.S.

Alekseev Psychiatrc Clinical Hospital No. 1

Kuzmenko A.Yu.

Alekseev Psychiatrc Clinical Hospital No. 1

Khannanova A.N.

Gilyarovsky Psychiatric Hospital, the branch of the Psychiatric Clinical Hospital No. 4 of the Moscow Health Department

Received:

17.03.2020

Accepted:

13.04.2020

List of references:

Psihiatricheskaya pomoshch’ bol’nym shizofreniej. Klinicheskoe rukovodstvo. Pod red. Krasnova V.N., Gurovicha I.Ya., Mosolova S.N., Shmuklera A.B. M.: Medpraktika-M; 2007. (In Russ.).
Gurovich IYa, Lyubov EB. Farmakoepidemiologiya i farmakoekonomika v psihiatrii. M.: Medpraktika-M; 2003. (In Russ.).
Standarty okazaniya pomoshchi bol’nym shizofreniej. Moskovskij NII psihiatrii Roszdrava. Pod red. Krasnova V.N., Gurovicha I.YA., Mosolova S.N., Shmuklera A.B. M.: Moskovskij NII psihiatrii; 2006. (In Russ.).
Kazakovtsev BA, Kostyuk GP, Plotnicou-Delesk M, Auzir S, Pak MV. Reorganization of psychiatric care in Rouen (France) and in Moscow (Russia). Bulletin of Neurology, Psychiatry and Neurosurgery. 2016;12:3-9. (In Russ.).
Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry. 2001;179:290-299.
Kostyuk GP, Reznik AM, Khannanova AN. Comparative analysis of pharmacotherapy sections of national clinical guidelines for the diagnosis and treatment of schizophrenia. Social and Clinical Psychiatry. 2015;25(1):87-97. (In Russ.).
Oehl M, Hummer M, Fleischhacker W. Compliance with antipsychotic treatment. Acta Psychiatrica Scandinavica, Supplementum. 2000;102:83-86.
Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Möller Hasan H, World A. Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013;14(1):2-44.
Heres St, Hamann J, Mendel R, Wickelmaier F, Pajonk FG, Leucht S, Kissling W. Identifying the profile of optimal candidates for antipsychotic depot therapy. A cluster analysis. Progress in NeuroPsychopharmacology & Biological Psychiatry. 2008;32:1987-1993.
Lyubov EB. Multilateral analysis of the efficacy of long-term treatment of schizophrenia with Rispolept Consta in everyday psychiatric practice (data from 12 months of treatment of patients in the Russian cohort of the international e-STAR study). Social and Clinical Psychiatry. 2011;3:66-73. (In Russ.).
Lafeuille MH, Laliberté-Auger F, Lefebvre P, Frois C, Fastenau J, Duh MS. Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. BMC Psychiatry. 2013;13:221.
Kuzmenko AY, Zaitseva MS, Kostyuk GP, Hannanova AN, Kurmyshev MV. Efficacy of long-acting antipsychotics in treatment of schizophrenia in patients with frequent hospitalizations. Social and Clinical Psychiatry. 2016;26(4):51-57. (In Russ.).
Bottlender R, Strauss A, Möller HJ. Association between psychopathology and problems of psychosocial functioning in the long-term outcome of patients diagnosed with schizophrenic, schizoaffective and affective disorders. Eur Arch Psychiat Clin Neurosci. 2013;263(2):85-92.
Chaturvedi SK, Gopinath PS, Mathai JP, Michael A. Negative symptoms and negative schizophrenia. Indian J Psychiat. 2010;26(3):200-205.
Olivares JM, Rodriguez-Morales A, Diels J, Povey M; e-STAR Spanish Study Group. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry. 2009;24(5):287-296.
Turner M, Eerdekens E, Jacko M, Eerdekens M. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol. 2004;19(4):241-249.
Danilov DS. Modern psychopharmacotherapeutic approaches to correction of negative disorders in patients with schizophrenia. Review of Psychiatry and Medical Psychology n.a. V.M. Bekhterev. 2014;3:69-79. (In Russ.).
Hanson E, Healey K, Wolf D, Kohler C. Assessment of pharmacotherapy for negative symptoms of schizophrenia. Curr Psychiat Rep. 2010;12(6):563-571.
Johnsen E, Jorgensen HA. Effectiveness of second generation antipsychotics: a systematic review of randomized trials. BMC Psychiatry. 2008;8:31.
Fusar-Poli P, Kempton MJ, Rosenheck RA. Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int Clin Psychopharmacol. 2013;28:57-66.
Schreiner A, Svensson A, Wapenaar R, Cherubin P, Princet P, Serazetdinova L, Zink M. Long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia: results from a prospective, 1-year, non-interventional study (InORS). World J Biol Psychiatry. 2014;15(7):534-545.
Franza F, Fasano V, De Guglielmo S, Solomita B. Management of primary negative symptoms in schizophrenia: an one-year observational study. Psychiatr Danub. 2015;27(suppl 1):245-249.

Close metadata